Published online Dec 15, 2019. doi: 10.4239/wjd.v10.i12.546
Peer-review started: July 26, 2019
First decision: August 19, 2019
Revised: October 20, 2019
Accepted: October 27, 2019
Article in press: October 27, 2019
Published online: December 15, 2019
Processing time: 143 Days and 5.2 Hours
Core tip: The results of this research suggest that the mitochondria targeted antioxidant 10-(6-plastoquinonyl) decyltriphenylphosphonium (SkQ1) might be a potential substance for incorporation into the antioxidant therapy of type 2 diabetes mellitus. The ability of this compound to lower the intensity of free-radical processes, acting as the key component of the pathogenesis of the type 2 diabetes mellitus, serves as the basis for this conclusion. Thus, after the introduction of SkQ1 to the animals with streptozotocin induced hyperglycemia, the values of the biochemiluminescence parameters reflecting the free-radical oxidation intensity, the concentration of diene conjugates and carbonyl products of protein oxidation, aconitate hydratase activity, and citrate content approached those of control values. At the same time, the activity level of the antioxidant enzymes superoxide dismutase and catalase approached those of normal values.